This site is intended only for Australian Healthcare Professionals
Menu
Close
ABRYSVO is also indicated for active immunisation of individuals 60 years of age and above for prevention of lower respiratory tract disease caused by RSV.1 Click here for more information.
Talk to your pregnant patients about maternal vaccination with ABRYSVO, and help protect infants against respiratory syncytial virus (RSV) from birth.1-2
ABRYSVO is indicated for the active immunisation of pregnant women (24-36 weeks gestation) for preventation of lower respiratory tract disease (LRTD) caused by RSV in infants (birth through 6 months of age).1
The highest number of RSV-coded hospitalisations occur in infants aged under 6 months in Australia.5
In Australia, infants are more than 12x likely to be admitted to hospital with RSV as children aged 1–4 years.5
ABRYSVO is indicated for:
![]() |
![]() |
![]() |
Pregnant woman receives ABRYSVO between weeks 24 and 36 of pregnancy.1 | Pregnant woman’s immune system produces antibodies, which are passed through the placenta to the foetus.1 | Infant is born with maternal antibodies, which help protect against LRTD caused by RSV from birth through 6 months.2 |
Lorem ipsum dolor sit amet, consectetur badipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Before prescribing, please review Product Information available here.
▼This vaccine is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems
PBS Information: This product is not listed on the National Immunisation Program (NIP) or the PBS
To access further materials, resources and receive communication about Pfizer medicines and vaccines.
The site is intended for Australian healthcare professionals.
©2023 Pfizer Australia Pty Ltd. Sydney, Australia. All rights reserved.
PP-UNP-AUS-0551 12/23.